Market Size of Injectable Drug Delivery Devices Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 114.85 Billion |
Market Size (2029) | USD 162.15 Billion |
CAGR (2024 - 2029) | 7.14 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Injectable Drug Delivery Devices Market Analysis
The Injectable Drug Delivery Devices Market size is estimated at USD 114.85 billion in 2024, and is expected to reach USD 162.15 billion by 2029, growing at a CAGR of 7.14% during the forecast period (2024-2029).
- The development of vaccines against COVID-19 is expected to significantly impact the growth of injectable drug delivery systems as a large-scale global vaccination program is underway, which has increased the demand for needles and syringes in the market. According to the June 2021 update from the Ministry of Health and Family Welfare of India, the Health Ministry has placed an order with the Serum Institute of India for 250 million doses of Covishield and with Bharat Biotech for 190 million doses of Covaxin to achieve universalization of vaccination in the country, which is expected to impact the market positively.
- Further, many companies launched new injectable drug delivery devices, which increased bioavailability and rapid and targeted drug delivery, which is also expected to significantly impact the growth of the studied market. Therefore, the COVID-19 pandemic significantly affected the market growth and is expected to have a significant impact on the growth of the injectable drug delivery devices market over the analysis period.
- The injectable drug delivery devices market is expected to show rapid growth due to the growing burden of chronic diseases, benefits, and convenience, leading to increased demand for self-injectors and growth of the biologics market, leading to increased demand for injectors.
- The growing burden of chronic diseases has led to a rise in the overall use of syringes, particularly disposable syringes. It has been observed that most deaths by chronic diseases can be attributed to cardiovascular diseases, obesity, and diabetes. This is expected to affect emerging countries the most, as population growth is found to be the most significant factor in developing areas. For instance, globally, lung cancer is anticipated to affect nearly 3.5 million by 2040, as per the Global Cancer Observatory data updated in March 2021.
- In addition, as per the data published by the American College of Chest Physicians in July 2021, lung cancer is one of the most frequently diagnosed cancers and accounts for 11.6% of the total cancer cases globally. Worldwide, lung cancer incidents are estimated to increase by 38%, to 2.89 million, by 2030. Due to the increasing burden of such chronic diseases, the demand for injectable drugs and therapies is growing, and it is expected to create new opportunities for injectable drug delivery devices and contribute to the market's growth over the forecast period.
- Furthermore, the launch of new technologically integrated products developed by key players that are focused on improving dosage administration will drive market growth. For instance, in January 2022, SHL Medical's official partner, Innovation Zed, for connected pen injector solutions, planned to launch InsulCheck DOSE, a connected add-on device that transforms traditional pen injectors into smart solutions to support the monitoring of disease management regimens. Such engagement of market players for the development of technologically advanced products will boost the market during the forecast period.
- Therefore, technological advancements, improving patient compliance, beneficial reimbursement policies, and the rise of biologics in the pharmaceutical industry are the factors contributing to the market's growth. However, injuries and infections caused by needles and the increasing use of alternative drug delivery systems are expected to hinder the market's growth.
Injectable Drug Delivery Devices Industry Segmentation
Injectable devices are being used to administer drugs intravenously, intramuscularly, or subcutaneously and are considered injectable drug delivery devices.
The injectable drug delivery devices market is segmented by device type (conventional drug delivery devices and self-injectable drug delivery devices), therapeutic application (cardiovascular devices, oncology, diabetes, autoimmune disorders, hepatitis, and other therapeutic applications), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD) for the above segments.
By Devices Type | |||||||
Conventional Drug Delivery Devices | |||||||
|
By Therapeutic Application | |
Cardiovascular Disease | |
Diabetes | |
Oncology | |
Autoimmune Disorders | |
Hepatitis | |
Other Therapeutic Applications |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Injectable Drug Delivery Devices Market Size Summary
The injectable drug delivery devices market is poised for significant growth, driven by the increasing demand for efficient drug administration methods and the rising prevalence of chronic diseases. The market is experiencing a surge in demand due to the development and distribution of COVID-19 vaccines, which has heightened the need for needles and syringes. This trend is further supported by the introduction of new devices that enhance bioavailability and enable rapid, targeted drug delivery. The growing burden of chronic conditions such as cardiovascular diseases, obesity, and diabetes is also contributing to the market's expansion, particularly in emerging economies where population growth is a significant factor. Technological advancements and the rise of biologics in the pharmaceutical industry are expected to further propel market growth, despite challenges such as needle-related injuries and the emergence of alternative drug delivery systems.
North America is expected to maintain a dominant position in the injectable drug delivery devices market, supported by an aging population and a high prevalence of chronic diseases. The region's established healthcare infrastructure and ongoing product innovations are key factors driving market growth. The United States, in particular, is witnessing increased demand for auto-injector pens and prefilled syringes, driven by the rising number of diabetes patients and the need for effective cancer therapies. The market is characterized by intense competition, with major players focusing on product innovations, strategic collaborations, and market expansions to enhance their market share. Continuous developments in injectable drug delivery systems, such as the launch of connected devices and safety systems, are expected to further stimulate market growth during the forecast period.
Injectable Drug Delivery Devices Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Burden of Chronic Diseases
-
1.2.2 Benefits and Convenience in Self Injectors
-
1.2.3 Growth of the Biologics Market Leading to Increased Demand for Injectors
-
-
1.3 Market Restraints
-
1.3.1 Injuries and Infections Caused by Needles
-
1.3.2 Increasing Use of Alternative Delivery Methods
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - in USD)
-
2.1 By Devices Type
-
2.1.1 Conventional Drug Delivery Devices
-
2.1.2 Advanced Drug Delivery Devices
-
2.1.2.1 Prefilled Syringes
-
2.1.2.2 Injectable Pens
-
2.1.2.3 Auto Injectors
-
2.1.2.4 Needle-free Injectors
-
2.1.2.5 Other Device Types
-
-
-
2.2 By Therapeutic Application
-
2.2.1 Cardiovascular Disease
-
2.2.2 Diabetes
-
2.2.3 Oncology
-
2.2.4 Autoimmune Disorders
-
2.2.5 Hepatitis
-
2.2.6 Other Therapeutic Applications
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Injectable Drug Delivery Devices Market Size FAQs
How big is the Injectable Drug Delivery Devices Market?
The Injectable Drug Delivery Devices Market size is expected to reach USD 114.85 billion in 2024 and grow at a CAGR of 7.14% to reach USD 162.15 billion by 2029.
What is the current Injectable Drug Delivery Devices Market size?
In 2024, the Injectable Drug Delivery Devices Market size is expected to reach USD 114.85 billion.